Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists
Authors:
Top Cited Papers
Open Access
- 3 March 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250802
Abstract
This cohort study compares the risks of developing different hematologic cancers in patients with type 2 diabetes treated with glucagon-like peptide–1 receptor agonists (GLP-1RAs) compared with metformin and insulin.Keywords
This publication has 6 references indexed in Scilit:
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesJAMA Network Open, 2024
- Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progressionAdvances in Biological Regulation, 2024
- Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trialsObesity Reviews, 2022
- The anti-inflammatory and immunological properties of GLP-1 Receptor AgonistsPharmacological Research, 2022
- Association between diabetes and haematological malignancies: a population-based studyDiabetologia, 2021
- Metformin targets multiple signaling pathways in cancerChinese Journal of Cancer, 2017